UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Meta-analysis of two randomized phase III trials (TCOG GI-0801 and ECRIN TRICS) of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2020, Vol.23 (1), p.160-167

2020

Volltextzugriff (PDF)

Association between the findings of metachronous secondary primary malignancies and the number of Lugol-voiding lesions

Diseases of the esophagus, 2020-09, Vol.33 (9)

2020

Volltextzugriff (PDF)

Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2019-01, Vol.22 (1), p.155-163

2019

Volltextzugriff (PDF)

A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma

International journal of clinical oncology, 2017-10, Vol.22 (5), p.905-912

2017

Volltextzugriff (PDF)

Alcohol abstinence and risk assessment for second esophageal cancer in Japanese men after mucosectomy for early esophageal cancer

PloS one, 2017-04, Vol.12 (4), p.e0175182-e0175182

2017

Volltextzugriff (PDF)

Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407)

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2016-07, Vol.19 (3), p.902-910

2016

Volltextzugriff (PDF)

A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2017-03, Vol.20 (2), p.350-357

2017

Volltextzugriff (PDF)

Correction to: Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2021-03, Vol.24 (2), p.477-478

2021

Volltextzugriff (PDF)

Usefulness of two-point fixed endoscopic submucosal dissection for superficial esophageal neoplasms

Esophagus : official journal of the Japan Esophageal Society, 2016-04, Vol.13 (2), p.182-186

2016

Volltextzugriff (PDF)

ENDOSCOPIC SUBMUCOSAL DISSECTION (TWO-POINT FIXED ESD) FOR EARLY ESOPHAGEAL CANCER

Digestive endoscopy, 2009-07, Vol.21 (3), p.176-179

2009

Volltextzugriff (PDF)

Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials

Clinical colorectal cancer, 2018-12, Vol.17 (4), p.e719-e732

2018

Volltextzugriff (PDF)

The clinicopathological significance of angiogenesis in hindgut neuroendocrine tumors obtained via an endoscopic procedure

Diagnostic pathology, 2016-11, Vol.11 (1), p.128-128, Article 128

2016

Volltextzugriff (PDF)

Association between macrocytosis and metachronous squamous cell carcinoma of the esophagus after endoscopic resection in men with early esophageal squamous cell carcinoma

Esophagus : official journal of the Japan Esophageal Society, 2020-04, Vol.17 (2), p.149-158

2020

Volltextzugriff (PDF)

Outcomes and precautions of endoscopic submucosal dissection for undifferentiated-type early gastric cancer

Therapeutic advances in gastroenterology, 2015-09, Vol.8 (5), p.255-262

2015

Volltextzugriff (PDF)

Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake

Japanese journal of clinical oncology, 2012-09, Vol.42 (9), p.787-793

2012

Volltextzugriff (PDF)

Meta-analysis of patient-level data on biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer with the TCOG GI-0801 BIRIP and ECRIN TRICS RCTs: protocol paper

Annals of Cancer Research and Therapy, 2017/08/08, Vol.25(2), pp.48-51

2017

Volltextzugriff (PDF)

Second-line Chemotherapy with Biweekly Paclitaxel after Failure of Fluoropyrimidine-based Treatment in Patients with Advanced or Recurrent Gastric Cancer: a Report from the Gastrointestinal Oncology Group of the Tokyo Cooperative Oncology Group, TCOG GC-0501 Trial

Japanese journal of clinical oncology, 2009-11, Vol.39 (11), p.713-719

2009

Volltextzugriff (PDF)

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

The New England journal of medicine, 2015-05, Vol.372 (20), p.1909-1919

2015

Volltextzugriff (PDF)

A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer

European journal of cancer (1990), 2018-03, Vol.91, p.86-91

2018

Volltextzugriff (PDF)

S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial

The lancet oncology, 2020-08, Vol.21 (8), p.1045-1056

2020

Volltextzugriff (PDF)

Clinical significance of evaluating primary lesions in patients with gastric cancer who receive chemotherapy

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2010-03, Vol.13 (1), p.36-42

2010

Volltextzugriff (PDF)

Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial

The lancet. Gastroenterology & hepatology, 2019-07, Vol.4 (7), p.501-510

2019

Volltextzugriff (PDF)

Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial

The lancet. Gastroenterology & hepatology, 2017-04, Vol.2 (4), p.277-287

2017

Volltextzugriff (PDF)

Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase III trial (TCOG GI-0801/BIRIP trial)

European journal of cancer (1990), 2014-05, Vol.50 (8), p.1437-1445

2014

Volltextzugriff (PDF)

A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601)

Cancer chemotherapy and pharmacology, 2012-02, Vol.69 (2), p.407-413

2012

Volltextzugriff (PDF)

1 – 25 von 63

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(50)

Publikationsform

Artikel
(63)

Sprache

Englisch
(58)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Humans
(34)
Science & Technology
(33)
Life Sciences & Biomedicine
(32)
Female
(28)
Middle Aged
(28)
Aged
(27)
Male
(26)
Oncology
(23)
Adult
(22)
Stomach Neoplasms - Drug Therapy
(21)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(19)
Gastric Cancer
(16)
Gastroenterology & Hepatology
(15)
Treatment Outcome
(15)
Stomach Neoplasms - Pathology
(14)
Chemotherapy
(13)
Gastroenterology
(13)
Cisplatin - Administration & Dosage
(12)
Medicine
(12)
Medicine & Public Health
(12)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Meta-analysis of two randomized phase III trials (TCOG GI-0801 and ECRIN TRICS) of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer

Association between the findings of metachronous secondary primary malignancies and the number of Lugol-voiding lesions

Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial

A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma

Alcohol abstinence and risk assessment for second esophageal cancer in Japanese men after mucosectomy for early esophageal cancer

Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407)

A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer

Correction to: Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial

Usefulness of two-point fixed endoscopic submucosal dissection for superficial esophageal neoplasms

ENDOSCOPIC SUBMUCOSAL DISSECTION (TWO-POINT FIXED ESD) FOR EARLY ESOPHAGEAL CANCER

Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials

The clinicopathological significance of angiogenesis in hindgut neuroendocrine tumors obtained via an endoscopic procedure

Association between macrocytosis and metachronous squamous cell carcinoma of the esophagus after endoscopic resection in men with early esophageal squamous cell carcinoma

Outcomes and precautions of endoscopic submucosal dissection for undifferentiated-type early gastric cancer

Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake

Meta-analysis of patient-level data on biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer with the TCOG GI-0801 BIRIP and ECRIN TRICS RCTs: protocol paper

Second-line Chemotherapy with Biweekly Paclitaxel after Failure of Fluoropyrimidine-based Treatment in Patients with Advanced or Recurrent Gastric Cancer: a Report from the Gastrointestinal Oncology Group of the Tokyo Cooperative Oncology Group, TCOG GC-0501 Trial

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer

S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial

Clinical significance of evaluating primary lesions in patients with gastric cancer who receive chemotherapy

Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial

Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial

Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase III trial (TCOG GI-0801/BIRIP trial)

A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601)

Suchergebnisse filtern